Table 2 Performance evaluation of the HIDEEP per the size of unlabeled datasets (AUROC).
From: HIDEEP: a systems approach to predict hormone impacts on drug efficacy based on effect paths
No. | Disease | AUROC | ||||
|---|---|---|---|---|---|---|
1 times | 3 times | 5 times | 7 times | 10 times | ||
1 | Acute Kidney Injury | 0.92 | 0.95 | 0.95 | 0.96 | 0.94 |
2 | Angina Pectoris | 0.87 | 0.87 | 0.87 | 0.87 | 0.87 |
3 | Atrial Fibrillation | 0.77 | 0.76 | 0.76 | 0.78 | 0.77 |
4 | Breast Neoplasms | 0.81 | 0.80 | 0.80 | 0.76 | 0.79 |
5 | Colonic Neoplasms | 0.89 | 0.91 | 0.90 | 0.87 | 0.90 |
6 | Diabetes Mellitus, Type 2 | 0.76 | 0.73 | 0.76 | 0.74 | 0.74 |
7 | Diabetic Nephropathies | 0.84 | 0.87 | 0.88 | 0.89 | 0.86 |
8 | Heart Failure | 0.95 | 0.94 | 0.92 | 0.93 | 0.93 |
9 | Hyperalgesia | 0.91 | 0.95 | 0.93 | 0.94 | 0.93 |
10 | Hyperglycemia | 0.96 | 0.98 | 0.98 | 0.98 | 0.97 |
11 | Hypertension | 0.85 | 0.87 | 0.89 | 0.88 | 0.87 |
12 | Hypotension | 0.92 | 0.92 | 0.91 | 0.91 | 0.93 |
13 | Lung Neoplasms | 0.89 | 0.93 | 0.92 | 0.95 | 0.95 |
14 | Myocardial Infarction | 0.91 | 0.91 | 0.91 | 0.90 | 0.92 |
15 | Ovarian Neoplasms | 0.94 | 0.98 | 0.97 | 0.96 | 0.98 |
16 | Postoperative Complications | 0.92 | 0.94 | 0.92 | 0.92 | 0.90 |
17 | Prostatic Neoplasms | 0.93 | 0.86 | 0.85 | 0.85 | 0.86 |
18 | Seizures | 0.84 | 0.83 | 0.83 | 0.82 | 0.83 |
19 | Tachycardia | 0.93 | 0.90 | 0.91 | 0.90 | 0.91 |
20 | Venous Thromboembolism | 0.91 | 0.93 | 0.90 | 0.91 | 0.89 |
| Â | Average | 0.89 | 0.89 | 0.89 | 0.89 | 0.89 |